Previous 10 | Next 10 |
home / stock / xrtxf / xrtxf news
● TMX-049 Results Show Beneficial Decrease of Urinary Albumin in T2DN ● CALGARY, Alberta, Sept. 19, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing inn...
● New Study Shows a Novel Form of Injury Linking Uric Acid Crystals in Urine and ADPKD Progression ● CALGARY, Alberta, Sept. 04, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmace...
NEW YORK , Aug. 5, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the August 1, 2019 OTCQB Venture Company Conference are now available for on-demand viewing at VirtualInvestorConfer...
Live OTCQB Venture Company Investor Conference August 1st Canada NewsWire NEW YORK, July 30, 2019 Company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 30, 2019 /CNW/ - Virtual Investor Conferences today a...
CALGARY, Alberta , July 30, 2019 /PRNewswire/ -- XORTX Therapeutics Inc. (" XORTX " or the " Company ") (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce ...
CALGARY, Alberta, July 18, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce th...
CALGARY, Alberta, July 15, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to recognize a...
CALGARY, Alberta, April 29, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed...
CALGARY, Alberta, April 16, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, congratulates the TODAY study team ...
CALGARY, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight a recent an...
News, Short Squeeze, Breakout and More Instantly...
XORTX Therapeutics Inc Company Name:
XRTXF Stock Symbol:
OTCMKTS Market:
XORTX Therapeutics Inc Website:
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to anno...
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...